Mark S. Robson, DPM
Podiatrists (Foot & Ankle Surgery Podiatrist)
- Medicare participating
At a glance
- Medical school
- California School of Podiatric Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 399
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: California School of Podiatric Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Foot & Ankle Surgery Podiatrist primary
TX license DPM1257
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St David's South Austin Medical Center Austin, TX
Medical groups
- Austin Podiatry PA (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 399
- Services billed
- 1,522
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 707 | 316 |
| New patient office or other outpatient visit, 30-44 minutes | 174 | 174 |
| X-ray of foot, minimum of 3 views | 68 | 57 |
| X-ray of foot, 2 views | 63 | 43 |
| Injection into tendon or ligament | 60 | 47 |
| Incision to lengthen toe tendon | 50 | 23 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 28 | 14 |
| Aspiration and/or injection of fluid from small joint | 25 | 17 |
| Injection of anesthetic and/or steroid drug into foot nerve | 20 | 17 |
| Removal of skin and tissue, 20.0 sq cm or less | 19 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Terbinafine Hcl Other prescribers in Austin, TX | 61 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Austin, TX | 32 |
| Cephalexin Other prescribers in Austin, TX | 23 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Austin, TX | 19 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Austin, TX | 15 |
| Azithromycin Other prescribers in Austin, TX | 14 |
| Ketoconazole Other prescribers in Austin, TX | 14 |
| Methylprednisolone Other prescribers in Austin, TX | 14 |
| Ammonium Lactate Other prescribers in Austin, TX | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 27 payments worth $745 in total to this clinician.
| Stryker Corporation | $279 |
|---|---|
| AbbVie Inc. | $157 |
| Treace Medical Concepts, Inc. | $73.27 |
| Amgen Inc. | $64.51 |
| DePuy Synthes Sales Inc. | $36.65 |
| Abbott Laboratories | $36.55 |
| Bone Support Inc. | $32.13 |
| Paratek Pharmaceuticals, Inc. | $30.88 |
| Food and Beverage | $745 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $944,783 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Randomized, Double-blind, Placebo controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.